VIDEO: International Lung Cancer Congress 'truly an amazing meeting'

ByMarley V. Ghizzone

Roy S. Herbst, MD, PhD, of Yale Cancer Center and Smilow Cancer Hospital, discussed lectures given by both the current president of the International Association for the Study of Lung Cancer, Tetsuya Mitsudomi, MD, and past president, Giorgio Scagliotti, MD, PhD.

Both lectures focused on personalized medicine, as well as perspective on where the field is headed and what the future of lung cancer care may look like.

“In 21 years of the meeting, we gone from chemotherapy alone in the metastatic setting to biomarker driven immunotherapy and now, the big get is we are moving all these therapies to the earlier stages of disease,” Herbst said. “Truly an amazing meeting.”

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interview

Disclosures: Herbst reports receiving research support from AstraZeneca, Eli Lilly and Company, Genentech/Roche and Merck and Company, and serving as a board member for Junshi Pharmaceuticals and as a consultant for Pharmaceuticals, ARMO Biosciences, AstraZeneca, Biodesix, Bolt Biotherapeutics, Bristol‐Myers Squibb, Cybrexa, Eli Lilly and Company, EMD Serono, Genentech/Roche, Genmab, Halozyme, Heat Biologics, IMAB Biopharma, Immunocore, Infinity Pharmaceuticals, Loxo Oncology, Merck and Company, Mirati Therapeutics, Nektar, Neon Therapeutics, NextCure, Novartis, Pfizer, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, Symphogen, Takeda, Tesaro, Tocagen and WindMIL Therapeutics.

Take Homes in Lung Cancer

Read more

VIDEO: International Lung Cancer Congress 'truly an amazing meeting'

Related Content